These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. COVID-19 and its implications for thrombosis and anticoagulation. Connors JM; Levy JH Blood; 2020 Jun; 135(23):2033-2040. PubMed ID: 32339221 [TBL] [Abstract][Full Text] [Related]
3. COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation. Miesbach W; Makris M Clin Appl Thromb Hemost; 2020; 26():1076029620938149. PubMed ID: 32677459 [TBL] [Abstract][Full Text] [Related]
4. Coagulopathy of Coronavirus Disease 2019. Iba T; Levy JH; Levi M; Connors JM; Thachil J Crit Care Med; 2020 Sep; 48(9):1358-1364. PubMed ID: 32467443 [TBL] [Abstract][Full Text] [Related]
6. Thromboinflammatory response in SARS-CoV-2 sepsis. Maiese A; Passaro G; Matteis A; Fazio V; Raffaele R; Paolo MD Med Leg J; 2020 Jul; 88(2):78-80. PubMed ID: 32490726 [TBL] [Abstract][Full Text] [Related]
7. Coagulation abnormalities and thrombosis in patients with COVID-19. Levi M; Thachil J; Iba T; Levy JH Lancet Haematol; 2020 Jun; 7(6):e438-e440. PubMed ID: 32407672 [No Abstract] [Full Text] [Related]
8. Fibrinogen and D-dimer variances and anticoagulation recommendations in Covid-19: current literature review. Hayıroğlu Mİ; Çınar T; Tekkeşin Aİ Rev Assoc Med Bras (1992); 2020 Jun; 66(6):842-848. PubMed ID: 32696883 [TBL] [Abstract][Full Text] [Related]
9. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action. Kollias A; Kyriakoulis KG; Dimakakos E; Poulakou G; Stergiou GS; Syrigos K Br J Haematol; 2020 Jun; 189(5):846-847. PubMed ID: 32304577 [TBL] [Abstract][Full Text] [Related]
10. Prevention and treatment of COVID-19-associated hypercoagulability: Recommendations of the Algerian society of transfusion and hemobiology. Chekkal M; Deba T; Hadjali S; Lamara H; Oulaa H; Zouai K; Hariti G Transfus Clin Biol; 2020 Nov; 27(4):203-206. PubMed ID: 33022374 [TBL] [Abstract][Full Text] [Related]
11. Risk Benefit Analysis in Reference to use of LMWH in COVID-19. Samajdar SS; Sam PA; Moitra S; Ray Y; Pal J; Joshi SR; Tripathi SK J Assoc Physicians India; 2020 Sep; 68(9):52-61. PubMed ID: 32798346 [TBL] [Abstract][Full Text] [Related]
12. Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia. Costanzo L; Palumbo FP; Ardita G; Antignani PL; Arosio E; Failla G; J Vasc Surg Venous Lymphat Disord; 2020 Sep; 8(5):711-716. PubMed ID: 32561465 [TBL] [Abstract][Full Text] [Related]
13. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Iba T; Connors JM; Levy JH Inflamm Res; 2020 Dec; 69(12):1181-1189. PubMed ID: 32918567 [TBL] [Abstract][Full Text] [Related]
14. [Clinical and coagulation characteristics in 7 patients with critical COVID-2019 pneumonia and acro-ischemia]. Zhang Y; Cao W; Xiao M; Li YJ; Yang Y; Zhao J; Zhou X; Jiang W; Zhao YQ; Zhang SY; Li TS Zhonghua Xue Ye Xue Za Zhi; 2020 Apr; 41(4):302-307. PubMed ID: 32447934 [No Abstract] [Full Text] [Related]
15. Coronavirus (COVID-19), Coagulation, and Exercise: Interactions That May Influence Health Outcomes. Zadow EK; Wundersitz DWT; Hughes DL; Adams MJ; Kingsley MIC; Blacklock HA; Wu SSX; Benson AC; Dutheil F; Gordon BA Semin Thromb Hemost; 2020 Oct; 46(7):807-814. PubMed ID: 32882720 [TBL] [Abstract][Full Text] [Related]
16. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Helms J; Tacquard C; Severac F; Leonard-Lorant I; Ohana M; Delabranche X; Merdji H; Clere-Jehl R; Schenck M; Fagot Gandet F; Fafi-Kremer S; Castelain V; Schneider F; Grunebaum L; Anglés-Cano E; Sattler L; Mertes PM; Meziani F; Intensive Care Med; 2020 Jun; 46(6):1089-1098. PubMed ID: 32367170 [TBL] [Abstract][Full Text] [Related]